Pooled Analysis Shows Elranatamab ‘Effective’ in Relapsed, Refractory Myeloma

By Patrick Daly - Last Updated: November 16, 2023

Elranatamab was effective and well-tolerated among patients with relapsed or refractory multiple myeloma (MM) who were previously treated with B-cell maturation antigen (BCMA)-targeted therapies, and no new safety signals were identified compared with BMCA-naïve patients, according to a pooled analysis of the MagnetisMM trial program.

The pooled analysis was presented during a poster presentation at JADPRO Live 2023 in Orlando, Florida.

The analysis included a total of 86 patients with a median age of 66 years (range, 40-84). The cohort was 47.7% male, and 24.4% had high-risk cytogenetics, 96.5% were triple-class refractory, and 54.7% were penta-drug refractory.

The overall objective response rate (ORR) with elranatamab monotherapy was 45.3% (95% CI, 34.6-56.5) with a complete response or better reported in 17.4% of patients. Additionally, the ORR in patients with prior antibody drug conjugate treatment was 41.4% (95% CI, 28.6-55.1) and was 52.8% (95% CI, 35.5-69.6) in those with prior chimeric antigen receptor (CAR) T-cell treatment.

The median time to response was 1.9 months (range, 0.3-9.3) in patients who responded. The median duration of response (DOR) was not reached at ten months, and the DOR rate at nine months was 72.4% (95% CI, 54.7-84.2).

Furthermore, the nine-month DOR rate in patients previously treated with ADC and CAR T-cell therapy was 67.3% (95% CI, 43.1-83.0) and 78.9% (95% CI, 53.2-91.5), respectively. The median overall survival (OS) rate at nine months was 60.1% (95% CI, 48.9-69.6), and median OS was not reached at ten months.

Listen to senior author on the study, Ajay Nooka, MD, FACP, from the Winship Cancer Institute of Emory University, discussing the approval of elranatamab with Blood Cancers Today.


Manier S, Lesokhin A, Mohty M, et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma an dprior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies. Poster presented at: JADPRO Live; November 9-12, 2023; Orlando, FL.

Post Tags:JADPRO 2023
Editorial Board